Edimer Pharmaceuticals Presents Update On Phase 2 Clinical Trial Of EDI200 At International Gathering Of Ectodermal Dysplasia Patient Foundations
4/1/2014 11:20:04 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced that Neil Kirby, Ph.D., President and Chief Executive Officer of Edimer, presented an update on the company’s lead compound, EDI200, to the International Ectodermal Dysplasia Network meeting in Milan, Italy. This tri-annual meeting is designed to promote international collaboration and share experiences related to the management of ectodermal dysplasias including XLHED, which is a serious and potentially life-threatening disorder associated with hyperthermia and clinically significant respiratory infections in addition to hair and tooth malformations. This was the first time the meeting was convened since a potential treatment entered evaluation in a clinical trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by